AstraZeneca: Enhertu (fam-Trastuzumab Deruxtecan-Nxki) Granted Priority Review in the US for Patients With Metastatic HER2-Positive Solid Tumors
January 30, 2024
January 30, 2024
WILMINGTON, Delaware, Jan. 30 -- AstraZeneca, a biopharmaceutical company, issued the following news release on Jan. 29, 2024:
AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for ENHERTU(R) (fam-trastuzumab deruxtecan-nxki) has been accepted and granted Priority Review in the US for the treatment of adult patients with unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment or who have . . .
AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for ENHERTU(R) (fam-trastuzumab deruxtecan-nxki) has been accepted and granted Priority Review in the US for the treatment of adult patients with unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment or who have . . .